Abstract
Purpose
CNS malignancies are currently the most common cause of disease related deaths in children. Although brainstem gliomas are invariably fatal cancers in children, clinical studies against this disease are limited. This review is to lead to a succinct collection of knowledge of known biological mechanisms of this disease and discuss available therapeutics.
Methods
A hallmark of brainstem gliomas are mutations in the histone H3.3 with the majority of cases expressing the mutation K27M on histone 3.3. Recent studies using whole genome sequencing have revealed other mutations associated with disease. Current standard clinical practice may merely involve radiation and/or chemotherapy with little hope for long term survival. Here we discuss the potential of new therapies.
Conclusion
Despite the lack of treatment options using frequently practiced clinical techniques, immunotherapeutic strategies have recently been developed to target brainstem gliomas. To target brainstem gliomas, investigators are evaluating the use of broad non-targeted therapy with immune checkpoint inhibitors. Alternatively, others have begun to explore adoptive T cell strategies against these fatal malignancies.
Similar content being viewed by others
References
Freeman CR, Farmer JP (1998) Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40(2):265–271
Cohen KJ et al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's oncology group. Neuro-Oncology 13(4):410–416
Ostrom QT et al (2015) Alex's lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology 16(Suppl 10):x1–x36
Donaldson SS, Laningham F, Fisher PG (2006) Advances toward an understanding of brainstem gliomas. J Clin Oncol 24(8):1266–1272
Freeman CR, Perilongo G (1999) Chemotherapy for brain stem gliomas. Childs Nerv Syst 15(10):545–553
Schwartzentruber J et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231
Wu G et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253
Sturm D et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437
Bender S et al (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24(5):660–672
Lewis PW et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340(6134):857–861
Wu G et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46(5):444–450
Pollack IF et al (2001) Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 61(20):7404–7407
Schroeder KM, Hoeman CM, Becher OJ (2014) Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res 75(1–2):205–209
Frappaz D et al (2008) Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro-Oncology 10(4):599–607
Liu YM et al (1998) Prognostic factors and therapeutic options of radiotherapy in pediatric brain stem gliomas. Jpn J Clin Oncol 28(8):474–479
Negretti L et al (2011) Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neuro-Oncol 104(3):773–777
Albright AL et al (1986) Prognostic factors in pediatric brain-stem gliomas. J Neurosurg 65(6):751–755
Farmer JP et al (2001) Brainstem gliomas. A 10-year institutional review. Pediatr Neurosurg 34(4):206–214
Chintagumpala M, Gajjar A (2015) Brain tumors. Pediatr Clin N Am 62(1):167–178
Mauffrey C (2006) Paediatric brainstem gliomas: prognostic factors and management. J Clin Neurosci 13(4):431–437
Sethi R et al (2011) Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neuro-Oncol 102(1):121–127
Singh R et al (2016) A novel magnetic resonance imaging segmentation technique for determining diffuse intrinsic pontine glioma tumor volume. J Neurosurg Pediatr 18(5):565–572
Chittiboina P et al (2014) Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr 13(3):276–282
Poretti A, Meoded A, Huisman TA (2012) Neuroimaging of pediatric posterior fossa tumors including review of the literature. J Magn Reson Imaging 35(1):32–47
Tisnado J et al (2016) Conventional and advanced imaging of diffuse intrinsic Pontine glioma. J Child Neurol 31(12):1386–1393
Albright AL et al (1993) Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer group. Neurosurgery 33(6):1026–1029 discussion 1029-30
Wen DY et al (1993) Targeted brain biopsy: a comparison of freehand computed tomography-guided and stereotactic techniques. Neurosurgery 32(3):407–412 discussion 412-3
McGirt MJ et al (2003) MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. Surg Neurol 59(4):277–281 discussion 281-2
Bernstein M, Parrent AG (1994) Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg 81(2):165–168
Quick-Weller J et al (2017) Benefit and complications of frame-based stereotactic biopsy in old and very old patients. World Neurosurg 102:442–448
Khuong-Quang DA et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–447
Buczkowicz P et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46(5):451–456
Elsasser SJ, Allis CD, Lewis PW (2011) Cancer. New epigenetic drivers of cancers. Science 331(6021):1145–1146
Castel D et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130(6):815–827
Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647(1–2):21–29
Margueron R, Reinberg D (2011) The Polycomb complex PRC2 and its mark in life. Nature 469(7330):343–349
Chan KM et al (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27(9):985–990
Li B et al (2009) Histone H3 lysine 36 dimethylation (H3K36me2) is sufficient to recruit the Rpd3s histone deacetylase complex and to repress spurious transcription. J Biol Chem 284(12):7970–7976
Barski A et al (2007) High-resolution profiling of histone methylations in the human genome. Cell 129(4):823–837
Monje M et al (2011) Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A 108(11):4453–4458
Taylor KR et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46(5):457–461
Gomes WA, Mehler MF, Kessler JA (2003) Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment. Dev Biol 255(1):164–177
Shore EM et al (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5):525–527
Shore EM, Kaplan FS (2011) Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva. Curr Osteoporos Rep 9(2):83–88
Chaikuad A et al (2012) Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 287(44):36990–36998
Hoeman, C.M., et al., ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nat Commun, 2019. 10(1): p. 1023
Parrales A, Iwakuma T (2015) Targeting oncogenic mutant p53 for Cancer therapy. Front Oncol 5:288
Lowe SW et al (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74(6):957–967
Lowe SW et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266(5186):807–810
Paugh BS et al (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29(30):3999–4006
Verhaak RG et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110
Sanai N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. World Neurosurg 74(1):4–5
Paugh BS et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28(18):3061–3068
Hashizume R et al (2014) Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20(12):1394–1396
Agger K et al (2007) UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449(7163):731–734
Hong S et al (2007) Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A 104(47):18439–18444
Hubner MR, Spector DL (2010) Role of H3K27 demethylases Jmjd3 and UTX in transcriptional regulation. Cold Spring Harb Symp Quant Biol 75:43–49
Ramaswamy V, Remke M, Taylor MD (2014) An epigenetic therapy for diffuse intrinsic pontine gliomas. Nat Med 20(12):1378–1379
Piunti A et al (2017) Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23(4):493–500
Herz HM et al (2014) Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science 345(6200):1065–1070
Marks PA et al (2004) Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 259:269–281 discussion 281-8
Grasso CS et al (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21(7):827
Hennika T et al (2017) Pre-clinical study of Panobinostat in Xenograft and genetically engineered murine diffuse intrinsic Pontine glioma models. PLoS One 12(1):e0169485
Nagaraja S et al (2017) Transcriptional dependencies in diffuse intrinsic Pontine glioma. Cancer Cell 31(5):635–652 e6
Pal S et al (2018) Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated DNA damage response to Radiosensitize pediatric high-grade gliomas. Cancer Res 78(14):4007–4021
Singleton WGB et al (2018) The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery. J Neurosurg Pediatr 22(3):288–296
Lin GL et al (2018) Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun 6(1):51
Lieberman NAP et al (2019) Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro-Oncology 21(1):83–94
Hwang WL et al (2018) Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 15(8):477–494
Bouffet E et al (2016) Immune checkpoint inhibition for Hypermutant glioblastoma Multiforme resulting from germline Biallelic mismatch repair deficiency. J Clin Oncol 34(19):2206–2211
Majzner RG et al (2017) Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 123(19):3807–3815
Wintterle S et al (2003) Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63(21):7462–7467
Hirano F et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65(3):1089–1096
Zeng J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343–349
Auvray M et al (2019) Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer 108:33–40
Zaretsky JM et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819–829
Skoulidis F et al (2018) STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8(7):822–835
Blumenthal DT et al (2016) Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neuro-Oncol 129(3):453–460
Kline C et al (2018) Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neuro-Oncol 140(3):629–638
Wildes TJ et al (2018) Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma. Clin Cancer Res 24(16):3955–3966
Morgan RA et al (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23(10):1043–1053
Maude SL et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517
Gardner RA et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322–3331
Zhou Z et al (2013) B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neuro-Oncol 111(3):257–264
Tang X et al (2019) B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics 14:279–287
Majzner RG et al (2019) CAR T cells targeting B7-H3, a pan-Cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 25(8):2560–2574
Mount CW et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med 24(5):572–579
Acknowledgements
This review was funded by the Michael Mosier Defeat DIPG Foundation (CF).
Availability of data and material
This review does not contain new unpublished data.
Code availability
No code was used to for this review.
Funding
This is review is funded by the Michael Mosier Defeat DIPG Foundation.
Author information
Authors and Affiliations
Contributions
BW and DW conducted literature searches and wrote the body; CF was responsible for editing, oversight, and funding.
Corresponding author
Ethics declarations
Conflict of interest
CF has interest in iOncologi, an immunobiology company.
Ethics approval
No ethics approval was required for this review.
Consent to participate
No consent was required for this review.
Consent for publication
No consent for publication was required for publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wummer, B., Woodworth, D. & Flores, C. Brain stem gliomas and current landscape. J Neurooncol 151, 21–28 (2021). https://doi.org/10.1007/s11060-020-03655-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-020-03655-w